GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Recommendation of “Hold” from Analysts

GoodRx Holdings, Inc. (NASDAQ:GDRX) has earned an average recommendation of “Hold” from the fifteen ratings firms that are covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $4.7292.

A number of analysts have recently issued reports on GDRX shares. UBS Group cut their price objective on GoodRx from $4.25 to $4.00 and set a “neutral” rating for the company in a research report on Thursday, November 6th. Wall Street Zen cut GoodRx from a “buy” rating to a “hold” rating in a research note on Sunday, January 25th. Mizuho reduced their price objective on shares of GoodRx from $5.00 to $4.00 and set a “neutral” rating for the company in a research report on Thursday, November 6th. Citigroup decreased their price objective on shares of GoodRx from $5.00 to $4.50 and set a “buy” rating on the stock in a report on Friday, January 9th. Finally, Jefferies Financial Group lowered shares of GoodRx to a “hold” rating in a research report on Thursday, January 22nd.

GoodRx Trading Down 0.8%

Shares of NASDAQ:GDRX opened at $2.36 on Friday. GoodRx has a 52-week low of $2.10 and a 52-week high of $5.81. The company has a debt-to-equity ratio of 0.81, a quick ratio of 3.11 and a current ratio of 3.11. The company has a market capitalization of $801.05 million, a P/E ratio of 26.22, a price-to-earnings-growth ratio of 0.90 and a beta of 1.50. The company has a 50-day simple moving average of $2.57 and a 200 day simple moving average of $3.33.

Institutional Investors Weigh In On GoodRx

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in shares of GoodRx by 7.3% during the third quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company’s stock worth $38,947,000 after acquiring an additional 624,182 shares during the period. Ameriprise Financial Inc. lifted its holdings in GoodRx by 4.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 4,819,505 shares of the company’s stock worth $24,001,000 after purchasing an additional 184,734 shares during the last quarter. LSV Asset Management boosted its stake in GoodRx by 20.0% in the 4th quarter. LSV Asset Management now owns 2,825,900 shares of the company’s stock valued at $7,658,000 after purchasing an additional 471,319 shares during the period. Dimensional Fund Advisors LP grew its holdings in GoodRx by 6.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,650,452 shares of the company’s stock valued at $7,183,000 after buying an additional 152,934 shares in the last quarter. Finally, Prescott Group Capital Management L.L.C. bought a new position in GoodRx during the 4th quarter worth $4,812,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.